PALIPALISADE BIO, INC.同业对比
PALISADE BIO, INC. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PALI本股 | $220M#8 | 1.9x#1 | 1.8x#8 | — | — | -16.2%#6 | — | -13.8%#3 | — | — | -31.1%#10 | — |
| SABS | $286M#2 | — | 1.4x#6 | — | -100.0%#8 | 138.9%#1 | — | 6.3%#1 | — | — | -2.3%#7 | — |
| LXEO | $267M#3 | — | 1.1x#5 | 407.7x#10 | — | -1.7%#5 | -16706.0%#10 | -42.5%#9 | — | — | -61.1%#15 | — |
| LCTX | $260M#4 | — | 4.3x#12 | 17.9x#6 | 53.2%#3 | -241.4%#14 | -251.6%#6 | -104.3%#13 | — | — | -43.3%#11 | — |
| ALEC | $256M#5 | — | — | 12.1x#5 | -79.1%#7 | -20.2%#7 | -741.3%#7 | — | — | — | 70.9%#2 | — |
| FATE | $255M#6 | — | 1.9x#9 | 38.4x#8 | -51.2%#6 | 26.8%#3 | -2222.4%#9 | -102.5%#12 | -131.3%#2 | — | 75.7%#1 | — |
| CABA | $306M#1 | — | 1.1x#4 | — | — | -44.9%#11 | — | -59.1%#10 | — | — | -47.4%#12 | — |
| DTIL | $225M#7 | 25.2x#3 | 4.4x#13 | 6.6x#4 | -50.1%#5 | -738.0%#16 | -152.2%#3 | -88.3%#11 | — | — | 20.9%#4 | — |
| IKT | $218M#9 | — | 1.4x#7 | — | -100.0%#8 | -75.4%#12 | — | -31.5%#6 | — | — | -2.8%#8 | — |
| PLX | $216M#10 | 11.7x#2 | 3.0x#10 | 4.1x#3 | -1.2%#4 | -325.2%#15 | -10.4%#1 | -9.2%#2 | -12.3%#1 | 3#1 | 14.3%#6 | — |
| ARTV | $207M#11 | — | 0.6x#1 | — | -100.0%#8 | -28.3%#8 | — | -24.1%#4 | — | — | 18.2%#5 | — |
| ACOG | $188M#12 | — | 3.6x#11 | 18.4x#7 | — | -39.8%#10 | -221.7%#5 | -39.0%#8 | — | — | 50.4%#3 | — |
| IVVD | $186M#13 | — | 1.0x#3 | 3.5x#2 | 110.5%#1 | 69.1%#2 | -104.0%#2 | -29.0%#5 | — | — | -54.5%#14 | — |
| LIMN | $169M#14 | — | 563.0x#14 | — | — | -187.8%#13 | — | -3395.2%#14 | -170.3%#3 | — | -96.0%#16 | — |
| STRO | $165M#15 | — | — | 1.6x#1 | 65.2%#2 | 15.9%#4 | -154.5%#4 | — | — | — | -3.2%#9 | — |
| TARA | $138M#16 | — | 0.9x#2 | 46.9x#9 | — | -28.7%#9 | -2189.6%#8 | -35.6%#7 | — | — | -49.5%#13 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-05。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议